Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Rocket Red who wrote (95593)	11/6/2001 8:50:15 PM
From: KZAP	Respond to of 150070

Quintek Forms New Subsidiary for Treating AIDS CAMARILLO, Calif.--(BUSINESS WIRE)--Oct. 22, 2001--Quintek Technologies, Inc. (OTCBB:QTEK - news) announced a major milestone established in its ongoing program to increase shareholder value by developing or acquiring new and unique technologies, establishing a subsidiary as a home for each technology, and spinning-off the subsidiary as an independent public company. Quintek has obtained the rights to distribute a proprietary line of therapeutics for the treatment of AIDS/HIV within third world countries. Although the therapies have not been fully tested and evaluated in formal trials, study trials have proven them to be very effective in reversing this condition. In addition, the therapies provide a number of benefits over conventional drug therapies in that they are low in cost, simple to administer, have minimal to no side effects, and are particularly suitable to support large scale patient treatment programs. To launch this technology, Quintek has formed ``PanaMed'' as a subsidiary, taking an initial 10% equity position through a stock swap transaction. Quintek plans to distribute the PanaMed shares to Quintek shareholders in the future as a key part of its spin-off strategy. PanaMed plans to conduct formal clinical trials in selected third world countries, with the first of these to commence early next year with over 2,000 participants. Upon completion of the first of these trials, PanaMed expects to launch an ongoing product approval and treatment program to progressively provide treatment access to the tens of millions of people infected with this disease. PanaMed holds an exclusive license to distribute the therapies. PanaMed will pursue a variety of sources for funding the treatments, including: 1) United Nations, 2) participating country governments, and 3) US and foreign humanitarian foundations. For more information on PanaMed, call 888/787-0485. *For the List. Huh? ;o) KZAP